Sanofi suspended its Phase 2 bronchiectasis study of SAR445399 in non-cystic fibrosis bronchiectasis, citing strategic business reasons. The trial began in April and targeted a reduction in mucus plug score; Sanofi said the pause was part of a company-wide portfolio review rather than a safety issue. The move underscores how quickly programs can be pulled before full readouts—especially for assets tied to IL-1 pathway biology—amid broader R&D resets following multiple clinical failures and leadership changes at the company.